It is dedicated to improving the lives of those affected by CNS disorders by optimizing the pharmacokinetic profiles of proven drugs to create novel therapeutics for use alone and as fixed-dose combination products.

Adamas has pioneered a platform to develop medicines for chronic neurologic disorders based upon an understanding of time-dependent biologic processes responsible for disease activity and drug response. They translate this understanding into medicines to provide demonstrable symptomatic relief from chronic neurologic disorders without additional tolerability issues.

The company has developed investigational product candidates, for treatment of levodopa-induced dyskinesia in Parkinson's disease, Alzheimer's disease, multiple sclerosis walking impairment, post-stroke walking impairment, epilepsy and several other indications.